Lynn Rutkowski

Lynn is a distinguished Neuroscientist and Pharmacologist with extensive expertise in Translational Medicine. She was formerly AVP of Translational Medicine at Wyeth in Collegeville, PA and co-led the Translational Medicine Research Collaboration in Scotland (TMRC). She was head of Product Development at Neuronyx in Malvern, PA working on mesenchymal stem cell products with the late Hubert Schoemaker, co-founder of Cenotcor, one of the first biotech companies to produce therapeutic monoclonal antibodies. Before joining industry, Lynn has over 15 years of academic research experience as a NIH-funded principal investigator with faculty appointments in Neurology at University of Pennsylvania, University of Michigan and Johns Hopkins University working on Schwann cell biology and Neurofibromatosis. Lynn received her PhD in Pharmacology and Toxicology with a focus on Neuropharmacology, from the University of Maryland, Baltimore.